Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 20/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21478151 | 1.00 | FOLH1 (0.54) | FOLH1 | |
| SCHEMBL18800206 | 0.97 | FOLH1 (0.51) | FOLH1 | |
| SCHEMBL22958142 | 0.97 | FOLH1 (0.51) | FOLH1 | |
| SCHEMBL21478153 | 0.94 | FOLH1 (0.49) | FOLH1 | |
| SCHEMBL15739387 | 0.93 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL18311344 | 0.93 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL17191797 | 0.93 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL19351983 | 0.93 | FOLH1 (0.46) | FOLH1 | |
| SCHEMBL19442800 | 0.93 | FOLH1 (0.51) | FOLH1 | |
| SCHEMBL18800205 | 0.93 | FOLH1 (0.51) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2021-05-27 | — | — | US | disclosed |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20180036364-A1 | METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND | ENDOCYTE INC (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2017205447-A1 | METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND | ENDOCYTE, INC. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036364-A1 | METHODS OF TREATING CANCER WITH A PSMA LIGAND-TUBULYSIN COMPOUND | FOLH1, TEK, TEKT1 | FOLH1 1/4885 |
| US-20210154311-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885 |
| US-20210154312-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885 |
| US-20190314515-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | FOLH1 1/4885 |
| US-10912840-B2 | Conjugates for treating diseases caused by PSMA expressing cells | FOLH1, KLK3, CD47 | FOLH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.